{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:25:02Z","timestamp":1785860702227,"version":"3.56.0"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1097\/01.cco.0000228741.64541.ca","type":"journal-article","created":{"date-parts":[[2006,5,22]],"date-time":"2006-05-22T05:21:42Z","timestamp":1148275302000},"page":"354-359","source":"Crossref","is-referenced-by-count":34,"title":["Targeting angiogenesis for the treatment of sarcoma"],"prefix":"10.1097","volume":"18","author":[{"given":"Lakshmi","family":"Balasubramanian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M","family":"Evens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210128","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1055\/s-2004-821183","article-title":"Soft tissue sarcoma in children and adolescents: experiences of the cooperative Soft Tissue Sarcoma Group Studies (CWS-81-96) [in German]","volume":"36","author":"Brecht","year":"2004","journal-title":"Handchir Mikrochir Plast Chir"},{"key":"R2-10-20210128","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/canjclin.55.1.10","article-title":"Cancer statistics 2005","volume":"55","author":"Jemal","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"R3-10-20210128","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1002\/1097-0142(197705)39:5<1940::AID-CNCR2820390505>3.0.CO;2-0","article-title":"Dose response evaluation of adriamycin in human neoplasia","volume":"39","author":"O'Bryan","year":"1977","journal-title":"Cancer"},{"key":"R4-10-20210128","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1200\/JCO.1989.7.1.126","article-title":"Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma","volume":"7","author":"Antman","year":"1989","journal-title":"J Clin Oncol"},{"key":"R5-10-20210128","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1200\/JCO.1993.11.7.1276","article-title":"An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas","volume":"11","author":"Antman","year":"1993","journal-title":"J Clin Oncol"},{"key":"R6-10-20210128","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/00000421-199806000-00025","article-title":"Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas","volume":"21","author":"Patel","year":"1998","journal-title":"Am J Clin Oncol"},{"key":"R7-10-20210128","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1200\/JCO.1993.11.7.1269","article-title":"Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas","volume":"11","author":"Edmonson","year":"1993","journal-title":"J Clin Oncol"},{"key":"R8-10-20210128","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1200\/JCO.2000.18.10.2081","article-title":"Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European organization for research and treatment of cancer soft tissue and bone sarcoma group","volume":"18","author":"Verweij","year":"2000","journal-title":"J Clin Oncol"},{"key":"R9-10-20210128","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/sonc.2002.37263","article-title":"Role of angiogenesis in tumor growth and metastasis","volume":"29","author":"Folkman","year":"2002","journal-title":"Semin Oncol"},{"key":"R10-10-20210128","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0092-8674(00)81848-6","article-title":"Endostatin: an endogenous inhibitor of angiogenesis and tumor growth","volume":"88","author":"O'Reilly","year":"1997","journal-title":"Cell"},{"key":"R11-10-20210128","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1097-2765(04)00102-9","article-title":"Endostatin's antiangiogenic signaling network","volume":"13","author":"Abdollahi","year":"2004","journal-title":"Mol Cell"},{"key":"R12-10-20210128","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3109\/08977199209023937","article-title":"The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies","volume":"7","author":"Kim","year":"1992","journal-title":"Growth Factors"},{"key":"R13-10-20210128","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-Trap: a VEGF blocker with potent antitumor effects","volume":"99","author":"Holash","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R14-10-20210128","doi-asserted-by":"crossref","first-page":"9073","DOI":"10.1073\/pnas.0403164101","article-title":"Effective inhibition of Rta expression and lytic replication of Kaposi's sarcoma-associated herpesvirus by human RNase P","volume":"101","author":"Zhu","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R15-10-20210128","first-page":"1","article-title":"SU11248, a multi-targeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, demonstrated antitumor activity in patients with metastatic renal cell carcinoma","volume":"24","author":"Motzer","year":"2005","journal-title":"J Clin Oncol"},{"key":"R16-10-20210128","first-page":"791","article-title":"Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines","volume":"27","author":"Onisto","year":"2005","journal-title":"Int J Oncol"},{"key":"R17-10-20210128","doi-asserted-by":"crossref","first-page":"8025","DOI":"10.1038\/sj.onc.1208939","article-title":"Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid","volume":"24","author":"Gee","year":"2005","journal-title":"Oncogene"},{"key":"R18-10-20210128","first-page":"3591","article-title":"Expression of vascular endothelial growth factor and its receptor, KDR\/Flk-1, in soft tissue sarcomas","volume":"25","author":"Pakos","year":"2005","journal-title":"Anticancer Res"},{"key":"R19-10-20210128","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.ejso.2005.04.012","article-title":"Microvessel density does not predict outcome in high grade soft tissue sarcoma","volume":"31","author":"West","year":"2005","journal-title":"Eur J Surg Oncol"},{"key":"R20-10-20210128","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/sj.bjc.6600201","article-title":"Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma","volume":"86","author":"Kaya","year":"2002","journal-title":"Br J Cancer"},{"key":"R21-10-20210128","first-page":"572","article-title":"Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis","volume":"6","author":"Kaya","year":"2000","journal-title":"Clin Cancer Res"},{"key":"R22-10-20210128","doi-asserted-by":"crossref","first-page":"8531","DOI":"10.1158\/1078-0432.CCR-04-0969","article-title":"Prognostic relevance of increased angiogenesis in osteosarcoma","volume":"10","author":"Kreuter","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R23-10-20210128","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1158\/1078-0432.CCR-04-1201","article-title":"Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family","volume":"11","author":"Dalal","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R24-10-20210128","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1158\/1078-0432.CCR-04-1206","article-title":"A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model","volume":"11","author":"Guan","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R25-10-20210128","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/annonc\/mdh309","article-title":"Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma","volume":"15","author":"Yoon","year":"2004","journal-title":"Ann Oncol"},{"key":"R27-10-20210128","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1200\/JCO.2005.10.022","article-title":"Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions","volume":"23","author":"Gasparini","year":"2005","journal-title":"J Clin Oncol"},{"key":"R28-10-20210128","doi-asserted-by":"crossref","first-page":"14888","DOI":"10.1073\/pnas.96.26.14888","article-title":"Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis","volume":"96","author":"Streit","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R29-10-20210128","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1053\/ejso.2000.0977","article-title":"Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group","volume":"26","author":"Werther","year":"2000","journal-title":"Eur J Surg Oncol"},{"key":"R30-10-20210128","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"R31-10-20210128","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer","volume":"23","author":"Miller","year":"2005","journal-title":"J Clin Oncol"},{"key":"R32-10-20210128","doi-asserted-by":"crossref","first-page":"7889","DOI":"10.1200\/JCO.2005.01.8234","article-title":"Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol"},{"key":"R33-10-20210128","doi-asserted-by":"crossref","first-page":"LBA4","DOI":"10.1200\/jco.2005.23.16_suppl.lba4","article-title":"Randomized phase II\/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial - E4599 [abstract].","volume":"16S","author":"Sandler","year":"2005","journal-title":"J Clin Oncol"},{"key":"R34-10-20210128","doi-asserted-by":"crossref","first-page":"7135","DOI":"10.1200\/JCO.2005.16.139","article-title":"Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas","volume":"23","author":"D'Adamo","year":"2005","journal-title":"J Clin Oncol"},{"key":"R35-10-20210128","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"R36-10-20210128","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0889-8588(03)00042-X","article-title":"Therapy of AIDS-associated Kaposi's sarcoma: targeting pathogenetic mechanisms","volume":"17","author":"Krown","year":"2003","journal-title":"Hematol Oncol Clin North Am"},{"key":"R37-10-20210128","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D'Amato","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R38-10-20210128","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1200\/JCO.2004.10.127","article-title":"Thalidomide: current role in the treatment of non-plasma cell malignancies","volume":"22","author":"Kumar","year":"2004","journal-title":"J Clin Oncol"},{"key":"R39-10-20210128","doi-asserted-by":"crossref","first-page":"5334","DOI":"10.1200\/JCO.2005.03.723","article-title":"Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma","volume":"23","author":"Vacca","year":"2005","journal-title":"J Clin Oncol"},{"key":"R40-10-20210128","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ygyno.2005.08.033","article-title":"Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium","volume":"100","author":"Yi-Shin Kuo","year":"2006","journal-title":"Gynecol Oncol"},{"key":"R41-10-20210128","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1258\/0956462981921512","article-title":"Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre","volume":"9","author":"Fife","year":"1998","journal-title":"Int J STD AIDS"},{"key":"R42-10-20210128","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1200\/JCO.2000.18.13.2593","article-title":"Activity of thalidomide in AIDS-related Kaposi's sarcoma","volume":"18","author":"Little","year":"2000","journal-title":"J Clin Oncol"},{"key":"R43-10-20210128","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1001\/archderm.139.2.178","article-title":"9-Cis-retinoic acid capsules in the treatment of AIDS-related Kaposi sarcoma: results of a phase 2 multicenter clinical trial","volume":"139","author":"Aboulafia","year":"2003","journal-title":"Arch Dermatol"},{"key":"R44-10-20210128","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/00002030-200202150-00014","article-title":"Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma","volume":"16","author":"Miles","year":"2002","journal-title":"AIDS"},{"key":"R45-10-20210128","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1002\/cncr.11009","article-title":"A multicenter phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunodeficiency syndrome-associated Kaposi's sarcoma","volume":"95","author":"Bernstein","year":"2002","journal-title":"Cancer"},{"key":"R46-10-20210128","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/sj.bjc.6602978","article-title":"Targeted therapy for metastatic renal cell carcinoma","volume":"94","author":"Patel","year":"2006","journal-title":"Br J Cancer"},{"key":"R48-10-20210128","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1200\/jco.2005.23.16_suppl.4000","article-title":"Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST [abstract]","volume":"16S","author":"Demetri","year":"2005","journal-title":"J Clin Oncol"},{"key":"R51-10-20210128","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1200\/JCO.2005.08.036","article-title":"Raf: a strategic target for therapeutic development against cancer","volume":"23","author":"Beeram","year":"2005","journal-title":"J Clin Oncol"},{"key":"R52-10-20210128","doi-asserted-by":"crossref","first-page":"5732","DOI":"10.1158\/1078-0432.CCR-04-0157","article-title":"Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas","volume":"10","author":"Heymach","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R53-10-20210128","first-page":"1648","article-title":"Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma","volume":"9","author":"Kuenen","year":"2003","journal-title":"Clin Cancer Res"},{"key":"R54-10-20210128","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood-2003-06-1930","article-title":"The effect of human tissue factor pathway inhibitor-2 on the growth and metastasis of fibrosarcoma tumors in athymic mice","volume":"103","author":"Chand","year":"2004","journal-title":"Blood"},{"key":"R55-10-20210128","first-page":"6723","article-title":"Antiangiogenic effects of latent antithrombin through perturbed cell\u2013matrix interactions and apoptosis of endothelial cells","volume":"60","author":"Larsson","year":"2000","journal-title":"Cancer Res"},{"key":"R56-10-20210128","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1097\/01.tp.0000187867.53355.fe","article-title":"Up-to-date epidemiological data and better treatment for Kaposi's sarcoma","volume":"80","author":"Alamartine","year":"2005","journal-title":"Transplantation"},{"key":"R57-10-20210128","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1200\/JCO.2004.08.064","article-title":"Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma","volume":"22","author":"Krown","year":"2004","journal-title":"J Clin Oncol"},{"key":"R58-10-20210128","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1200\/JCO.2000.18.4.716","article-title":"Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma","volume":"18","author":"Tulpule","year":"2000","journal-title":"J Clin Oncol"},{"key":"R59-10-20210128","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1200\/JCO.2005.11.043","article-title":"Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team","volume":"23","author":"Noy","year":"2005","journal-title":"J Clin Oncol"},{"key":"R60-10-20210128","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1200\/JCO.2005.06.079","article-title":"Imatinib-induced regression of AIDS-related Kaposi's sarcoma","volume":"23","author":"Koon","year":"2005","journal-title":"J Clin Oncol"},{"key":"R61-10-20210128","first-page":"153","article-title":"Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study","volume":"20","author":"Cianfrocca","year":"2002","journal-title":"J Clin Oncol"},{"key":"R62-10-20210128","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000063378","article-title":"Treatment of Kaposi's sarcoma with human chorionic gonadotropin","volume":"204","author":"Simonart","year":"2002","journal-title":"Dermatology"},{"key":"R63-10-20210128","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1200\/JCO.1998.16.4.1444","article-title":"Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study","volume":"16","author":"Dezube","year":"1998","journal-title":"J Clin Oncol"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00007890-200605270-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:31:09Z","timestamp":1785857469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001622-200607000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.cco.0000228741.64541.ca","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}